For such applications, researchers have recently focused on lipid nanoparticles (LNPs) as particularly potent vehicles for RNA delivery. This is particularly exciting in the context of improving cancer therapies. Despite their extensive use in mRNA vaccines during the COVID-19 pandemic, these tiny, fatty couriers face significant challenges that must be addressed for improved therapeutic outcomes. A recent study in Nature Communications shows just how powerful lipid nanoparticles can be. At the same time, it shines a light on their shortcomings, creating opportunities for future improvements.
Lipid nanoparticles have now been injected into billions of people with few, if any, associated safety signals. Their use in mRNA vaccines has significantly raised interest in their use for other medical treatments. While lipid nanoparticles have become ubiquitous, they too are not without limitations. These challenges limit the ability to deliver RNA and gene-editing tools safely and effectively, which are sometimes referred to as “gene scissors.”
Challenges in Targeted Delivery
The study’s authors, including Johanna Johansson from Lund University, emphasize that lipid nanoparticles must overcome two primary challenges: accurately guiding to the correct cellular destination and avoiding entrapment in endosomes. Endosomes are small cellular compartments that commonly sequester exogenous materials, inhibiting productive release to target sites.
Johansson expressed excitement about the study’s findings on how lipid nanoparticles need to disrupt the endosome membrane. She noted, “We discovered in this study that lipid nanoparticles have to puncture open the endosome, and this disruption enables them to deliver their RNA cargo directly into the cytosol, the interior of the cell. Even after making a hole, we were surprised to discover that only a minuscule fraction of RNA is delivered into cytosol from the endosome. This further underscores a major flaw in the process.
The Holy Grail of Oncology
Anders Wittrup, a researcher at the Department of Clinical Sciences and the Wallenberg Center for Molecular Medicine at Lund University, is enthusiastic about the possibilities offered by mRNA and gene scissors. He calls their targeted delivery “the Holy Grail in oncology.” Most importantly, he described the need to optimize delivery methods to increase treatment efficacy.
Wittrup explained, “A drug delivery vehicle must reach the tissue that you want to treat, introduce enough RNA material, and reach a sufficient number of cells. It must be effective.” He expressed optimism about future advancements: “What we have seen from the study can help to advance the technique. We have identified those steps that must be improved and be more effective so that we can use lipid nanoparticles to reach more tissues in the body and thereby treat more diseases.”
The ripple effect of such an accomplishment could be felt well beyond oncology. Scientists are currently working to develop novel ways to distribute RNA in the whole body. This pioneering effort has the potential to radically change therapeutic approaches for a variety of medical illnesses.
Future Directions and Optimizations
With recent advances in lipid nanoparticles, the future looks bright. We will need to improve them substantially to be able to deploy them productively in therapeutic applications. The newly published research shows that improving the delivery process would pave the way for groundbreaking advancements in genetic therapies.
Wittrup elaborated on this potential, stating, “We will have the capacity to rewrite the genetic code when it is misspelled. The technique is already available. The delivery method must be optimized, and here lipid nanoparticles offer a possible solution.” Here’s how scientists are pushing the envelope on novel strategies and technologies. Lipid nanoparticles have been key in this research and have important, exciting implications for medicine.
